

General Certificate of Education (A-level) June 2013

Biology

**BIOL1** 

(Specification 2410)

**Unit 1: Biology and Disease** 

## Final



PMT

Mark schemes are prepared by the Principal Examiner and considered, together with the relevant questions, by a panel of subject teachers. This mark scheme includes any amendments made at the standardisation events which all examiners participate in and is the scheme which was used by them in this examination. The standardisation process ensures that the mark scheme covers the students' responses to questions and that every examiner understands and applies it in the same correct way. As preparation for standardisation each examiner analyses a number of students' scripts: alternative answers not already covered by the mark scheme are discussed and legislated for. If, after the standardisation process, examiners encounter unusual answers which have not been raised they are required to refer these to the Principal Examiner.

It must be stressed that a mark scheme is a working document, in many cases further developed and expanded on the basis of students' reactions to a particular paper. Assumptions about future mark schemes on the basis of one year's document should be avoided; whilst the guiding principles of assessment remain constant, details will change, depending on the content of a particular examination paper.

Further copies of this Mark Scheme are available from: aqa.org.uk

Copyright © 2013 AQA and its licensors. All rights reserved.

## Copyright

AQA retains the copyright on all its publications. However, registered schools/colleges for AQA are permitted to copy material from this booklet for their own internal use, with the following important exception: AQA cannot give permission to schools/colleges to photocopy any material that is acknowledged to a third party even for internal use within the school/college.

Set and published by the Assessment and Qualifications Alliance.

The Assessment and Qualifications Alliance (AQA) is a company limited by guarantee registered in England and Wales (company number 3644723) and a registered charity (registered charity number 1073334). Registered address: AQA, Devas Street, Manchester M15 6EX.

| Question | Marking Guidelines  | Marks | Comments  |
|----------|---|-------|---|
| 1(a)     | 1. <b>A</b> : phospholipid (layer);   | 2     | <ol> <li>Reject hydrophobic /<br/>hydrophilic phospholipid</li> </ol>   |
|          | <ol> <li>B: pore/channel/pump/carrier/<br/>transmembrane/intrinsic/transport<br/>protein;</li> </ol>  |       | <ol> <li>Ignore unqualified<br/>reference to protein</li> </ol>   |
| 1(b)(i)  | Condensation (reaction);  | 1     |   |
| 1(b)(ii) | <ul> <li>Organelle named; Function in protein production/secretion;</li> <li>eg</li> <li>1. Golgi (apparatus);</li> <li>2. Package/process proteins;</li> <li><i>OR</i></li> <li>3. Rough endoplasmic reticulum/ribosomes;</li> <li>4. Make polypeptide/protein/forming peptide bonds;</li> <li><i>OR</i></li> <li>5. Mitochondria;</li> <li>6. Release of energy/make ATP;</li> <li><i>OR</i></li> <li>7. Vesicles;</li> <li>8. Secretion/transport of protein;</li> </ul> | 2     | <ul> <li>Function must be for organelle<br/>named<br/>Incorrect organelle = 0</li> <li>1. Accept smooth<br/>endoplasmic reticulum</li> <li>3. Accept alternative<br/>correct functions of<br/>rough endoplasmic<br/>reticulum. ER/RER is<br/>insufficient</li> <li>3. Accept folding<br/>polypeptide/protein</li> <li>6. Reject produce/make<br/>energy</li> <li>6. Accept produce energy<br/>in the form of ATP</li> </ul> |

| Question | Marking Guidelines   | Marks | Comments   |
|----------|--|-------|--|
| 2(a)     | <ol> <li>(Enzyme has) <u>active site;</u></li> <li>Only substrate fits (the active site);</li> </ol>                       | 2     | <ol> <li>Reject active site is<br/>same shape as substrate</li> <li>Reject active site is on<br/>the substrate</li> <li>Accept active site forms<br/>during induced fit</li> </ol>                   |
|          |  |       | 2. Accept converse statement   |
| 2(b)     | <ol> <li>(Allopurinol) is a similar shape to<br/>xanthine;</li> </ol>  | 3     | Assume "it" = allopurinol<br>1. Reject <u>same</u> shape.<br>Accept similar structure  |
|          | <ol> <li>(Allopurinol) enters active site / is a<br/>competitive inhibitor;</li> </ol>                                     |       | <ol> <li>Ignore e-s complexes in relation to inhibitor</li> <li>Reject non-competitive inhibitor in the context of binding to the active site</li> </ol>   |
|          | <ol> <li>Less xanthine binds/fewer e-s<br/>complexes/fewer uric acid crystals<br/>formed/less uric acid formed;</li> </ol> |       | <ol> <li>Ignore<br/>complementary/fits</li> <li>Reject <u>no</u> e-s<br/>complexes/xanthine<br/><u>cannot</u> enter active site,<br/><u>no</u> uric acid</li> <li>Can award in context of</li> </ol> |
|          |  |       | non-competitive<br>inhibition  |

| Question | Marking Guidelines   | Marks | Comments   |
|----------|--|-------|--|
| 3(a)(i)  | (Simple) diffusion;  | 1     | Reject facilitated<br>diffusion<br>Accept lipid diffusion  |
| 3(a)(ii) | <ol> <li>Thin walls/cells;</li> <li>(Total) surface area is large;</li> </ol>                      | 2     | <ol> <li>'Short diffusion pathway'<br/>alone is an explanation<br/>not a description</li> <li>Accept squamous<br/>epithelia / one cell thick</li> <li>Ignore references to<br/>'volume ratio'</li> </ol> |
| 3(b)     | <ol> <li>Loss of elasticity/elastic tissue;</li> <li>Scar tissue;</li> <li>Less recoil;</li> </ol> | 2 max | 1. Accept elastin  |

| Question | Marking Guidelines   | Marks | Comments   |
|----------|--|-------|--|
| 4(a)     | <ol> <li>Toxin (produced by bacterium)<br/>causes (chloride) ions to move into<br/>(lumen of) intestine;</li> <li><u>Water potential</u> (of intestine<br/>contents) falls / water moves by<br/><u>osmosis</u> into intestine/out of cells;</li> </ol>   | 2     | <ol> <li>Reject incorrect ion</li> <li>Direction of ion<br/>movement must be clear</li> <li>Ignore movement of<br/>water from blood (rather<br/>than cells)</li> </ol>                     |
| 4(b)     | <ol> <li>Both show little/no increase/remain<br/>constant in January/February;</li> <li>(Up to May) sea temperature rises<br/>more quickly/before increase in<br/>cholera;</li> <li>Both reach a peak in/decline after<br/>April/May;</li> </ol>   | 2 max | Ignore references to correlation<br>Accept May to June   |
| 4(c)     | <ol> <li>Positive correlation from January to<br/>September/October (between sea<br/>temperature and cholera cases);</li> <li>Only records people in hospital with<br/>cholera / may be people with<br/>cholera not in hospital;</li> <li>Negative correlation/cases rising as<br/>sea temperature falls in<br/>October/November;</li> </ol> | 2 max | <ol> <li>Ignore as sea<br/>temperature rises,<br/>cholera cases rise, as in<br/>stem</li> <li>Accept any two months<br/>within range</li> <li>'At end of year'<br/>insufficient</li> </ol> |

| 4(d) | <ul> <li>Suitable suggestion with explanation;;</li> <li>1. Have produced memory cells;</li> <li>2. After previous infection/vaccination;</li> <li>OR</li> </ul> | 2 | <ol> <li>'Have become immune'<br/>is not enough</li> <li>Accept 'produces<br/>secondary response'</li> </ol> |
|------|--|---|--|
|      | <ol> <li>Different forms of cholera;</li> <li>Some don't produce much/any</li> </ol>   |   | <ol> <li>Accept types /strains<br/>/variety</li> </ol>   |
|      | toxins;  |   |  |
|      | OR   |   |  |
|      | 5. Few bacteria ingested;  |   |  |
|      | <ol> <li>Not enough toxin to produce<br/>symptoms;</li> </ol>  |   |  |
|      | OR   |   |  |
|      | <ol> <li>Some people naturally resistant to<br/>bacterium;</li> </ol>  |   |  |
|      | <ol> <li>Because of structure of cell<br/>membranes / amount of secretions<br/>eg bile/pancreatic juices;</li> </ol>   |   |  |

| Question | Marking Guidelines   | Marks | Comments  |
|----------|--|-------|---|
| 5(a)     | <ol> <li>To allow comparison;</li> <li>Because different number of cells in<br/>samples / different times for<br/>incubation / numbers become easier<br/>to manipulate;</li> </ol>               | 2     |   |
| 5(b)     | 203.7(%);;   | 2     | Allow 1 mark for 21.8/10.7<br>Allow 1 mark for correct answer<br>(203.74) but not correctly to 1<br>dp<br>204= 1 mark |
| 5(c)(i)  | <ol> <li>(At every concentration) uptake is<br/>faster at 37°C/at higher temperature;</li> <li>Due to faster respiration/ATP<br/>production;</li> </ol>  | 2     |   |
| 5(c)(ii) | <ol> <li>Uptake at 37°C only small increase<br/>/levelling off/almost constant;</li> <li>As carrier proteins full;</li> <li>Concentration of imatinib is not the<br/>limiting factor;</li> </ol> | 2 max | Accept 'no (significant) change'<br>Ignore use of numbers   |

| Question | Marking Guidelines   | Marks | Comments   |
|----------|--|-------|--|
| 6(a)     | <ol> <li>Add iodine/potassium iodide solution<br/>to the food sample;</li> <li>Blue/black/purple indicates starch is<br/>present;</li> </ol>   | 2     | <ol> <li>Allow 'iodine'</li> <li>Must be in the context of<br/>the correct reagent</li> </ol>  |
| 6(b)     | <ol> <li>Starch digested to maltose/by<br/>amylase;</li> <li>Maltose digested to glucose/by<br/>maltase;</li> <li>Digestion of sucrose is a single<br/>step/only one enzyme/sucrase;</li> </ol>  | 3     | Ignore 'hard to digest/easily<br>digested'<br>3. Accept converse for<br>starch<br>3. Do not accept digestion<br>of sucrose is faster |
| 6(c)     | <ol> <li>Smoking increases risk of CHD;</li> <li>Introduces another variable;</li> </ol>   | 1 max |  |
| 6(d)(i)  | <ol> <li>No effect on risk with diet group 1<br/>and 2/lowest glycaemic load;</li> <li>Above diet group 2/in higher groups,<br/>risk increases as glycaemic load<br/>increases;</li> </ol>   | 1 max | Simple statement of correlation is not enough for this mark  |
| 6(d)(ii) | <ol> <li>For diet group 2 and above,<br/>increase in risk of CHD as GL<br/>increases;</li> <li>(Higher GL diets lead to) more<br/>(harmful) lipids (in blood), so greater<br/>risk of atheroma;</li> <li>Atheroma leads to blockage of<br/><u>coronary artery</u> / increased risk of<br/>blood clot in <u>coronary artery</u>;</li> </ol> | 2 max | Ignore reference to lipids in diet<br>Ignore references to myocardial<br>infarction/heart attack                                     |

| Question | Marking Guidelines  | Marks | Comments  |
|----------|---|-------|---|
| 7(a)     | <ol> <li>Microvilli;</li> <li>Carrier proteins/co-transport<br/>proteins/membrane-bound<br/>enzymes;</li> <li>Many mitochondria;</li> </ol>   | 2 max | 1. Accept large surface<br>area   |
|          |   |       | Accept lots of ATP produced   |
| 7(b)(i)  | Substance that causes an immune response/production of antibodies;  | 1     | Ignore foreign/non-self   |
| 7(b)(ii) | <ol> <li>Not lipid soluble;</li> <li>Too large (to diffuse through the membrane);</li> <li>Antigens do not have the complementary shape/cannot bind to receptor/channel/carrier proteins (in membranes of other epithelial cells);</li> </ol>   | 2 max |   |
| 7(c)     | <ol> <li>(Vaccine contains)<br/>antigen/attenuated/dead pathogen;</li> <li>Microfold cells take up/bind and<br/>present/transport antigen (to<br/>immune system/lymphocytes/T-<br/>cells);</li> <li>T-cells activate B-cells;</li> <li>B-cells divide/form clone/undergo<br/>mitosis;</li> <li>B-cells produce antibodies;</li> <li>Memory cells produced;</li> <li>More antibodies/antibodies<br/>produced faster in secondary<br/>response/on reinfection;</li> </ol> | 5 max | <ol> <li>Reject if in context of<br/>injection of vaccine</li> <li>Accept T-cells release<br/>cytokines</li> <li>Accept plasma cells for<br/>B-cells</li> <li>Ignore T/B in reference<br/>to memory cells</li> <li>Must be comparative</li> </ol> |

| Question | Marking Guidelines | Marks  | Comments |   |
|----------|--------------------|--|----------|---|
| 8(a)     | 1.                 | SAN sends wave of electrical activity / impulses (across atria) causing atrial contraction;                            | 5        | Accept excitation   |
|          | 2.                 | Non-conducting tissue prevents<br>immediate contraction of<br>ventricles/prevents impulses<br>reaching the ventricles; |          |   |
|          | 3.                 | AVN delays (impulse) whilst blood leaves atria/ventricles fill;  |          |   |
|          | 4.                 | (AVN) sends wave of electrical activity / impulses down Bundle of His;   |          | 4. Allow Purkyne<br>fibres/tissue   |
|          | 5.                 | Causing ventricles to contract from base up;   |          |   |
| 8(b)     | 1.                 | Atrium has higher pressure than ventricle (due to filling/contraction);  | 5 max    | Start anywhere in sequence, but events must be in the correct order.  |
|          | 2.                 | Atrioventricular valve opens;  |          | <ol> <li>Accept bicuspid, reject<br/>tricuspid</li> </ol>   |
|          | 3.                 | Ventricle has higher pressure than atrium (due to filling/contraction);  |          | <ol> <li>Allow: blood passes<br/>through the valve = valve<br/>open / blood stopped<br/>from passing through the</li> </ol> |
|          | 4.                 | Atrioventricular valve closes;   |          | valve = valve closed  |
|          | 5.                 | Ventricle has higher pressure than aorta;  |          | <ol> <li>'prevents backflow' is not<br/>enough</li> </ol>   |
|          |                    |  |          | Points 1, 3, 5, and 7 must be comparative: eg high <u>er</u>  |
|          | 6.                 | Semilunar valve opens;   |          | 6. Allow aortic valve   |
|          | 7.                 | Higher pressure in aorta than ventricle (as heart relaxes);  |          | Marks 2, 4, 6, 8 given in the correct sequence can gain 4 marks   |
|          | 8.                 | Semilunar valve closes;  |          | 8. Allow aortic valve   |
|          |                    |  |          | <ol> <li>'prevents backflow' is not<br/>enough</li> </ol>   |
|          | 9.                 | (Muscle/atrial/ventricular)<br><u>contraction</u> causes increase in<br>pressure;                                      |          |   |